Trial Profile
A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 25 Aug 2023 Planned number of patients changed from 60 to 150.
- 25 Aug 2023 Planned End Date changed from 21 Aug 2023 to 21 Aug 2024.
- 25 Aug 2023 Planned primary completion date changed from 21 Aug 2023 to 21 Aug 2024.